External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<p>About the stock: Lupin is a multinational pharma company engaged in manufacturing &amp; marketing branded &amp; generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms &amp; therapeutic categories.</p>
<ul>
<li>It is the third largest generic player (by prescriptions) in the US with 168 generic products (market leader: 52 products; Top 3: 122 products) along with being sixth largest company in Indian pharmaceutical market</li>
<li>Lupin is the largest manufacturer of anti-TB drugs in the world and enjoys global leadership in anti-TB &amp; Cephalosporins</li>
</ul>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

About the stock: Lupin is a multinational pharma company engaged in manufacturing &amp; marketing branded &amp; generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms &amp; therapeutic categories.

It is the third largest generic player (by prescriptions) in the US with 168 generic products (market leader: 52 products; Top 3: 122 products) along with being sixth largest company in Indian pharmaceutical market
Lupin is the largest manufacturer of anti-TB drugs in the world and enjoys global leadership in anti-TB &amp; Cephalosporins

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin Ltd: India, Milestone Buoy Numbers but US Below-Par